Kps-0373    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
18脊髄小脳変性症(多系統萎縮症を除く。)8

18. 脊髄小脳変性症(多系統萎縮症を除く。) [臨床試験数:59,薬物数:78(DrugBank:28),標的遺伝子数:44,標的パスウェイ数:59
Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 59 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02889302
(ClinicalTrials.gov)
November 15, 201631/8/2016An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373;Drug: PlaceboKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/AAll203Phase 3Japan
2NCT01970098
(ClinicalTrials.gov)
October 9, 201322/10/2013A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low dose;Drug: PlaceboKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/AAll374Phase 3Japan
3NCT01970137
(ClinicalTrials.gov)
October 201322/10/2013A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low doseKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABothPhase 3Japan
4NCT01970124
(ClinicalTrials.gov)
October 201322/10/2013A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low doseKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABothPhase 3Japan
5NCT01970111
(ClinicalTrials.gov)
October 201322/10/2013An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low doseKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABothPhase 3Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01384435
(ClinicalTrials.gov)
June 201123/6/2011A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCDSCDDrug: KPS-0373;Drug: PlaceboKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABoth200Phase 2Japan
7NCT01004016
(ClinicalTrials.gov)
October 200927/10/2009A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCDSpinocerebellar DegenerationDrug: KPS-0373;Drug: PlaceboKissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABoth20Phase 2Japan
8NCT00863538
(ClinicalTrials.gov)
November 200416/3/2009Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)An Open-label, Phase II Study of KPS-0373 in Patients With SCDSpinocerebellar DegenerationDrug: KPS-0373Kissei Pharmaceutical Co., Ltd.NULLCompleted20 YearsN/ABoth40Phase 2Japan